Drug Profile
FMAU
Alternative Names: 18F-FMAU; 2'-fluoro-5-methylarabinosyluracil; FM-ara-U; NSC 678516Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Bristol-Myers Squibb; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Antivirals; Arabinonucleosides; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action DNA synthesis inhibitors; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Herpes simplex virus infections; Solid tumours
Most Recent Events
- 18 Jul 2011 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
- 18 Jul 2011 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 30 May 1995 Preclinical for Herpes simplex virus infections in USA (unspecified route)